English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the current study, we assessed the relationship between mutations and the blood cell counts and early progression of patients with diffuse large-B cell lymphoma (DLBCL). A total of 109 patients with newly diagnosed DLBCL were included in this study.  UBE2A  mutation was only found in patients with bone marrow involvement. The mutations of  ZNF608 ,  SF3B1 ,  DTX1 , and  NCOR2  were related to blood cell counts . NCOR2  mutations were only detected in patients of the noncomplete response group (PR + SD + PD). In addition, the mutations of  ATM ,  BTG2 ,  TBL1XR1 , and  TP53  were linked to lower PFS/OS rate, while  SGK1 ,  SCOS1 , and  NFKBIE  were related to higher PFS/OS rate. Importantly, we identified that Ann Arbor stage (III–IV), B symptoms, absolute lymphocyte count (ALC) abnormity, and  MTOR  mutation were the four independent influencing factors of the 12-month progression of DLBCL patients. Overall, this study revealed that mutations were associated with the early progression of DLBCL.

leukemia and lymphoma

Targeted sequencing reveals the relationship between mutations and patients’ clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma